Women taking the contraceptive pill 'more likely to be depressed'
ConclusionThis was a large prospective cohort study which aimed to investigate whether using hormonal contraception is associated with the future use of antidepressants and a diagnosis of depression.The researchers compared users of hormonal contraception with non-users and found users were more likely to be prescribed antidepressants and diagnosed with depression. However, there are a few important points to consider about the results, such as: this study is not able to prove that the contraceptive methods are responsible for the depression – only to find possible links to investigate further some of the associations are based on a comparatively small number of events the risk of using antidepressants and being diagnosed with depression peaks at approximately two to three months of contraceptive use, but then begins to fall The researchers tested for a range of other things that might explain the results. For example, they looked at whether doctors were more likely to prescribe hormonal contraception to women who were already low in mood, or whether the initiation of a sexual relationship might influence the risk of depression. They found nothing that could easily explain the link that was shown across all age groups and types of contraception.Further studies are required to prove this link. If the link is proven in future studies, depression may have to be added as a possible side effect of hormonal contraception. Links To The Headlines Women taking pill more ...
Aeyung Kim, Jin Yeul Ma
Conclusion Blood type A was found as a risk factor for MI. Higher arachidonic acid-induced aggregation in group O and higher PRI in group A against aspirin and P2Y12 inhibitor treatment, respectively, may suggest alternative antiplatelet therapies for PRs with these blood types.
Conclusion For patients with very long native coronary artery disease, R-ZES and EES implantation showed comparable angiographic and clinical outcomes through 1 year of follow-up.
Gilead Sciences Inc. landed former Roche executive Daniel O'Day as its new CEO, and Genentech Inc.'s current CEO will take O'Day's role with Genentech's parent company in a game of musical chairs disclosed Sunday. The job shuffling has implications up and down the employment ranks of the Bay Area's two largest drug makers during critical times for both companies. Gilead (NASDAQ: GILD), based in Foster City, is set up for deeper moves into next-generation cancer drugs while South San Francisco's…
[Monitor] It is common among mothers who give birth to premature babies [at fewer than 37 weeks] to find difficulty producing breast milk immediately. In this case, experts require specifically human breast milk to increase the baby's survival chances.
[Monitor] Kampala -The number of women delivering in health facilities has doubled in the last 16 years, the Uganda Demographic and Health Survey (UDHS) report reveals.
Two people developed cancer after organ donations from a woman who had the undetected disease.
This study explores the prevalence of clonal hematopoiesis related to radioactive iodine exposure and how it impacts overall survival in patients with thyroid cancer.Journal of Clinical Endocrinology &Metabolism
Suicide rates among the U.S. working age population have been increasing. Are workers in certain occupations at greater risk?Morbidity &Mortality Weekly Report
Training programs are needed to help employers improve communication with cancer survivors and facilitate workplace accommodations.Journal of the National Cancer Institute